Dyne Therapeutics (DYN) reported new clinical efficacy data from two separate mid to late-stage studies evaluating its two clinical-stage pipeline candidates, DYNE-101 and DYNE-251, in patients with myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping, respectively. New clinical data from both studies demonstrated a meaningful impact on key biomarkers and functional improvement in multiple clinical endpoints that matter to patients. We remind the investo ...